Approved labelZOLADEX 3.6 mg prescribing information for its approved oncology and gynecologic indications
PopulationAdults covered by the approved ZOLADEX indications
DoseOne 3.6 mg implant
RouteSubcutaneous implant in the upper abdominal wall by a healthcare professional
FrequencyEvery 28 days
DurationIndication-specific; the label specifies 6 months for endometriosis
PreparationReady-to-use 3.6 mg implant supplied in a single-dose prefilled syringe; no reconstitution.